A

PriceAerovate Therapeutics

AVTE

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.

Historical stock price chart and annual return over the past years

-89%

4 years

% Total

AVTE
-42%

4 years

Annual Return

AVTE